MannKind grants Tolero Pharmaceuticals rights to its BTK program for cancer and inflammation
Executive Summary
MannKind Corp. (therapeutics for diabetes and cancer) has granted start-up Tolero Pharmaceuticals Inc. (drug discovery based on genetic pathway abnormalities) exclusive worldwide rights to its Bruton’s tyrosine kinase (BTK) program, which is in preclinical studies for blood cancers and inflammatory diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice